GT 2227

Drug Profile

GT 2227

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gliatech (CEASED)
  • Class Antidepressants; Antihistamines; Neuroprotectants; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 02 Feb 2017 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 23 Dec 2003 Suspended - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 24 Aug 2001 No-Development-Reported for Attention-deficit hyperactivity disorder in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top